CRBN and plasma cell myeloma: This limitation presents multiple challenges for the clinical application of PROTACs, including drug resistance due to CRBN mutations in multiple myeloma and treatment failure resulting from VHL dysfunction in clear cell renal carcinoma [47, 48].